Caraglia Michele

Summary

Affiliation: Second University of Naples
Country: Italy

Publications

  1. ncbi eIF5A isoforms and cancer: two brothers for two functions?
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, 16, 80138, Naples, Italy
    Amino Acids 44:103-9. 2013
  2. ncbi Molecular targets for the treatment of multiple myeloma
    Marco Rossi
    Medical Oncology, Magna Graecia University and T Campanella Cancer Center, Salvatore Venuta Campus, 88100, Catanzaro, Italy
    Curr Cancer Drug Targets 12:757-67. 2012
  3. ncbi 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress
    Monica Lamberti
    Occupational Medicine, Hygiene and Industrial Toxicology Section, Department of Experimental Medicine, Second University of Naples, Naples, Italy
    J Exp Clin Cancer Res 31:60. 2012
  4. ncbi Nanotech revolution for the anti-cancer drug delivery through blood- brain-barrier
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Curr Cancer Drug Targets 12:186-96. 2012
  5. ncbi Tumour-specific uptake of anti-cancer drugs: the future is here
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Curr Drug Metab 13:4-21. 2012
  6. ncbi Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports
    Liliana Montella
    Medical Oncology Unit San Giovanni di Dio Hospital, 80020 Frattaminore, Naples, Italy
    J Exp Clin Cancer Res 28:7. 2009
  7. ncbi High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases
    Velia D'Angelo
    Pediatric Oncology Service, Pediatric Department, F Fede, II University of Naples, Naples, Italy
    J Exp Clin Cancer Res 28:39. 2009
  8. ncbi Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways
    M Caraglia
    Department of Biochemistry and Biophysics, II University of Naples, 80138, Naples, Italy
    Curr Cancer Drug Targets 9:690-704. 2009
  9. ncbi Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Cell Death Dis 2:e150. 2011
  10. ncbi Alpha-interferon and its effects on signal transduction pathways
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, Naples, Italy
    J Cell Physiol 202:323-35. 2005

Collaborators

Detail Information

Publications89

  1. ncbi eIF5A isoforms and cancer: two brothers for two functions?
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, 16, 80138, Naples, Italy
    Amino Acids 44:103-9. 2013
    ..eIF5A-1 and/or the eIF5A-2 isoform may serve as a new molecular diagnostic or prognostic marker or as a molecular target for anti-cancer therapy...
  2. ncbi Molecular targets for the treatment of multiple myeloma
    Marco Rossi
    Medical Oncology, Magna Graecia University and T Campanella Cancer Center, Salvatore Venuta Campus, 88100, Catanzaro, Italy
    Curr Cancer Drug Targets 12:757-67. 2012
    ..In conclusion, the use of MTD in the treatment of MM is a promising approach but still far from becoming a current indication: a new dawn is arising with still unpredictable results...
  3. ncbi 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress
    Monica Lamberti
    Occupational Medicine, Hygiene and Industrial Toxicology Section, Department of Experimental Medicine, Second University of Naples, Naples, Italy
    J Exp Clin Cancer Res 31:60. 2012
    ..Cardiotoxicity is a major complication of anticancer drugs, including anthracyclines and 5-fluorouracil(5-FU) and it can have detrimental effects both in patients and workers involved in the preparation of chemotherapy...
  4. ncbi Nanotech revolution for the anti-cancer drug delivery through blood- brain-barrier
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Curr Cancer Drug Targets 12:186-96. 2012
    ..This review summarizes the most meaningful advances in the field of nanotechnologies for brain delivery of drugs...
  5. ncbi Tumour-specific uptake of anti-cancer drugs: the future is here
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Curr Drug Metab 13:4-21. 2012
    ..In conclusion, a new avenue in anti-cancer treatment has been disclosed with the use of DDS...
  6. ncbi Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports
    Liliana Montella
    Medical Oncology Unit San Giovanni di Dio Hospital, 80020 Frattaminore, Naples, Italy
    J Exp Clin Cancer Res 28:7. 2009
    ..Chondrosarcomas and chordomas are usually chemoresistant bone tumors and may have a poor prognosis when advanced. They are usually associated with worsening pain difficult to control...
  7. ncbi High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases
    Velia D'Angelo
    Pediatric Oncology Service, Pediatric Department, F Fede, II University of Naples, Naples, Italy
    J Exp Clin Cancer Res 28:39. 2009
    ..These results demonstrate an involvement of these proteins in survival of blast cells and, consequently, on relapse percentages of the different subgroups of patients...
  8. ncbi Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways
    M Caraglia
    Department of Biochemistry and Biophysics, II University of Naples, 80138, Naples, Italy
    Curr Cancer Drug Targets 9:690-704. 2009
    ..These observations open a new scenario of anticancer intervention able to strengthen the antitumor activity of IFN-alpha or to use more potent type I IFNs...
  9. ncbi Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
    M Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Cell Death Dis 2:e150. 2011
    ..The determination of both the oxidative stress status and pERK activity in PBMC has high value in the prediction of response to sorafenib+octreotide therapy in HCC patients...
  10. ncbi Alpha-interferon and its effects on signal transduction pathways
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, Naples, Italy
    J Cell Physiol 202:323-35. 2005
    ..These data strongly suggest that the specific disruption of the latter could be a useful approach to potentiate the antitumour activity of IFNalpha against human tumors based on the new mechanistic insights achieved in the last years...
  11. ncbi Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview
    Monica Marra
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    J Transl Med 9:171. 2011
    ....
  12. ncbi Translational and post-translational modifications of proteins as a new mechanism of action of alpha-interferon: review article
    M Caraglia
    Dipartimento di Biochimica e Biofisica, Seconda Universita di Napoli, Naples, Italy
    Amino Acids 26:409-17. 2004
    ....
  13. ncbi The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate
    Michele Caraglia
    Department of Biochemistry and Biophysics, II University of Naples, Via Costantinopoli no 16, 80138 Naples, Italy
    Oncogene 23:6900-13. 2004
    ....
  14. ncbi Zoledronic acid: an unending tale for an antiresorptive agent
    Michele Caraglia
    II University of Naples, Department of Biochemistry and Biophysics, Via S M Costantinopoli 16, 80138 Naples, Italy
    Expert Opin Pharmacother 11:141-54. 2010
    ..ZOL blocks protein isoprenylation, a pleiotropic and basic biochemical process within the cells regulating the activity of several proteins involved in survival and proliferating pathways...
  15. ncbi Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress
    M Marra
    Department of Biochemistry and Biophysics, School of Medicine, Second University of Naples, Via Costantinopoli 16, 80138 Naples, Italy
    Biochim Biophys Acta 1783:2269-78. 2008
    ..These data allow the design of new therapeutic strategy based on the use of this combination in human neoplasms...
  16. ncbi The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells
    M Caraglia
    Department of Biochemistry and Biophysics, II University of Naples, Via Costantinopoli 16, 80132, Naples, Italy
    J Biochem (Tokyo) 133:757-65. 2003
    ..These data suggest that the apoptosis induced by IFNalpha could be regulated by eIF-5A that, therefore, could represent a useful target for the potentiation of IFNalpha antitumor activity...
  17. ncbi Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects
    M Marra
    Department of Biochemistry and Biophysics, II University of Naples, Via Costantinopoli no16, 80138 Naples, Itlay
    Curr Cancer Drug Targets 9:791-800. 2009
    ..Finally, a new scenario of integrated bio-medicine and pharmacology will be depicted in order to drive the optimization of anti-cancer activity of N-BPs...
  18. ncbi The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis
    M Caraglia
    Dipartimento di Biochimica e Biofisica, , Italy
    Amino Acids 20:91-104. 2001
    ..Finally, we propose eIF-5A as an additional target of anti-cancer strategies...
  19. ncbi Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products
    M Marra
    Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours Fondaz G Pascale, Naples, Italy
    Amino Acids 33:273-81. 2007
    ..In conclusion, polyamine metabolites could be useful in the design of new therapeutic strategies...
  20. ncbi C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A
    A Lamberti
    Department of Biochemistry and Medical Biotechnology, Federico II University of Naples, Naples, Italy
    Cell Death Differ 14:952-62. 2007
    ..The dynamic simulation of 3Dstructure of eEF-1A identified putative serine and threonine phosphorylation sites. In conclusion, the interaction between eEF-1A and C-Raf increases eEF-1A stability and induces a survival activity...
  21. ncbi Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells
    M Caraglia
    Department of Experimental Oncology, National Institute of Tumours Fondazione G Pascale, Naples, Italy
    Front Biosci 10:2566-75. 2005
    ..These data suggest the use of the combination in these therapeutic settings even if further experiments are required for the clinical translation...
  22. ncbi EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells
    M Caraglia
    Dipartimento di Biochimica e Biofisica, , Naples, Italy
    Cell Death Differ 10:218-29. 2003
    ..The selective targeting of this pathway appears to be a promising approach in order to enhance the antitumor activity of IFNalpha...
  23. ncbi Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation
    M Caraglia
    Dipartimento di Biochimica e Biofisica, , Italy
    Eur J Biochem 267:3919-36. 2000
    ..Finally, we propose a new multimodal strategy against cancer based on the simultaneous intervention on protein synthesis and signal transduction...
  24. ncbi Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy
    M Caraglia
    Department of Biochemistry and Biophysics F Cedrangolo, Second University of Naples, Italy
    Adv Exp Med Biol 472:187-98. 1999
    ..The data strongly suggest that the post-translational modifications of eIF-5A could be a suitable target for the potentiation of the activity of anti-cancer agents...
  25. ncbi Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide
    L Montella
    Medical Oncology Unit, S Giovanni di Dio Hospital, Via Giovanni XXIII, Frattamaggiore, Naples, Italy
    Eur J Cancer Care (Engl) 19:200-4. 2010
    ..The reduced need for daily administration of colony-stimulating factors, blood sampling, antibiotic therapy and hospitalization has a significant impact in terms of both quality of life and pharmaco-economic evaluations...
  26. ncbi R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation
    Michele Caraglia
    Experimental Pharmacology Unit, National Cancer Institute of Naples Fondazione G Pascale, Naples, Italy
    J Cell Physiol 211:533-43. 2007
    ....
  27. ncbi Structural organization of the human eukaryotic initiation factor 5A precursor and its site-directed variant Lys50-->Arg
    P Stiuso
    Department of Biochemistry and Biophysics, Second University of Naples, Italy
    Amino Acids 16:91-106. 1999
    ..Spectroscopic data showed that these intermediates are differently structured. Consequently, the two proteins seem to have different unfolding pathways...
  28. ncbi Targeting Raf-kinase: molecular rationales and translational issues
    M Caraglia
    National Cancer Institute Fondazione G. Pascale, Experimental Oncology Department, Experimental Pharmacology Unit, Naples, Italy
    Ann Oncol 17:vii124-7. 2006
    ..In conclusion, Raf-kinase appears an appealing therapeutic target, even it other preclinical and clinical studies are warranted in order to evaluate the activity of sorafenib both in monotherapy and in combination with other agents...
  29. ncbi Self-assembly nanoparticles for the delivery of bisphosphonates into tumors
    G Salzano
    Department of Pharmaceutical and Toxicological Chemistry, Universita degli Studi di Napoli Federico II, Naples, Italy
    Int J Pharm 403:292-7. 2011
    ..Finally, in an animal model of prostate cancer, a significant reduction of tumor growth was achieved with pre-PLCaPZ NPs, while the tumor was unaffected by ZOL in solution...
  30. ncbi Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells
    S Naviglio
    Department of Biochemistry and Biophysics, II University of Naples, 80138 Naples, Italy
    J Interferon Cytokine Res 27:129-36. 2007
    ..Therefore, this pathway could represent a target to enhance the antitumor activity of IFN-alpha...
  31. ncbi Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience
    L Montella
    San Giovanni di Dio Hospital, Naples, Italy
    Oncol Rep 20:385-90. 2008
    ..Statistically significant correlation was found between serum VEGF and tumor progression. In conclusion, the combination of RFA and octreotide was active in advanced HCC, however, confirmation in a larger series is required...
  32. ncbi Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water
    M Costantino
    CE RI S T Center of Thermal Researches and Studies srl, Naples, Italy
    Amino Acids 36:161-5. 2009
    ....
  33. ncbi Current approaches and perspectives in the therapy of medullary thyroid carcinoma
    G Vitale
    Department of Molecular and Clinical Endocrinology and Oncology, School of Medicine, University of Naples Federico II, Naples, Italy
    Cancer 91:1797-808. 2001
    ..However, at present, surgery is the only curative treatment for MTC...
  34. ncbi Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract
    G Palmieri
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Amino Acids 32:395-400. 2007
    ....
  35. ncbi The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE)
    G Facchini
    Medical Oncology Division B, National Cancer Institute, Naples, Italy
    J Exp Clin Cancer Res 26:307-12. 2007
    ..019). ZOL addition induces a clinical benefit and improves QoL of patients with bone metastases. Moreover, the occurrence of bone clinical response is related to a reduced risk of SREs...
  36. ncbi Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells
    Monica Marra
    Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy
    Int J Cancer 125:2004-13. 2009
    ..In the same experimental conditions, CYR61 protein downregulation potentiated the inactivation of the Ras-dependent proliferation pathway and cell cycle inhibitors p21 and p27 expression...
  37. ncbi Theophylline-induced apoptosis is paralleled by protein kinase A-dependent tissue transglutaminase activation in cancer cells
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli, Naples, Italy
    J Biochem 132:45-52. 2002
    ..Therefore, a mechanistic model of theophylline action and anti-tumour strategies based on the concomitant use of theophylline and agents that potentiate tTGase activity can be hypothesized...
  38. ncbi The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways
    Michele Caraglia
    Experimental Pharmacology Unit, Experimental Oncology Department, National Cancer Institute Fondazione G Pascale, Naples, Italy
    Int J Cancer 121:2317-30. 2007
    ....
  39. ncbi Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A)
    A M Facchiano
    Dipartimento di Biochimica e Biofisica, Centro di Ricerca Interdipartimentale di Scienze Computazionali e Biotecnologiche, Seconda Universita di Napoli, Via Costantinopoli 16, 80138 Napoli, Italy
    Protein Eng 14:881-90. 2001
    ..Last, the model was deposited in the Protein Data Bank to be accessible for studies on the structure-function relationships of the human eIF-5A...
  40. ncbi Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase
    A Budillon
    Experimental Pharmacology Unit, Department of Experimental Oncology, National Cancer Institute Fondazione G Pascale, Naples, Italy
    Curr Drug Targets 6:337-51. 2005
    ..This review will focus on the most important issues in the development of both these classes of agents...
  41. ncbi Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells
    M Boccellino
    Dipartimento di Biochimica e Biofisica, Seconda Universita di Napoli, Naples, Italy
    J Cell Physiol 201:71-83. 2004
    ..Furthermore, we have demonstrated that EGF is able to antagonize these effects through the inhibition of caspase-3 activation...
  42. ncbi Protein kinase A as a biological target in cancer therapy
    Silvio Naviglio
    Second University of Naples, Medical School, Department of Biochemistry and Biophysics, Via L De Crecchio 7, 80138 Naples, Italy
    Expert Opin Ther Targets 13:83-92. 2009
    ..since it has been implicated in the initiation and progression of many tumors, PKA has been suggested as a novel molecular target for cancer therapy...
  43. ncbi Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells
    Silvio Naviglio
    Department of Biochemistry and Biophysics, Second University of Naples, Medical School, Via L De Crecchio 7, Naples, Italy
    Cancer Biol Ther 8:1183-90. 2009
    ....
  44. ncbi Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer
    M Sagristani
    Division of Haematology, S Gennaro Hospital, ASL Napoli 1, Naples, Italy
    J Exp Clin Cancer Res 26:291-2. 2007
    ..The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy...
  45. ncbi Mediastinal images resembling thymus following 131-I treatment for thyroid cancer
    L Montella
    Medical Oncology Department, S Giovanni di Dio Hospital, via Pirozzi, 80027 Frattaminore, Naples, Italy
    Monaldi Arch Chest Dis 63:114-7. 2005
    ..This evaluation is presented together with some hypotheses on the relationships between thymus and thyroid. Moreover, some considerations are made on the differential diagnosis between thymus and mediastinal tumour thyroid residues...
  46. ncbi The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article
    A Lamberti
    Dipartimento di Biochimica e Biotecnologie Mediche, , Naples, Italy
    Amino Acids 26:443-8. 2004
    ..This article summarizes the present knowledges on the several extra-translational roles of eEF1A also in order to understand as the protein synthesis regulatory mechanisms could offer tools for cancer intervention...
  47. ncbi Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution
    M Caraglia
    Dipartimento di Oncologia Sperimentale, Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy
    Amino Acids 35:275-81. 2008
    ..In this paper we have reported structural characterization of VIP by experimental and computational methods as well as a comparative analysis of the peptide with its transglutaminase catalyzed analog VIP-Diaminopropane (VIP-DAP)...
  48. ncbi P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia
    F Casale
    Pediatric Oncology Service, Pediatric Department, II University of Naples, 80138 Napoli, Italy
    Oncol Rep 12:1201-7. 2004
    ..Moreover, MDR1 function was also a predictor of response, but only in univariate analysis...
  49. ncbi Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
    R V Iaffaioli
    INT G Pascale, Naples, Italy
    Br J Cancer 92:1621-5. 2005
    ..Toxicity of treatment was low. Our study confirms that treatment with sequential hormonal agents can extend the period of time during which endocrine therapy can be used, thereby deferring the decision to use chemotherapy...
  50. ncbi Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo
    Raffaele Addeo
    Pediatric Oncology Service, Pediatric Department, II University of Naples, Napoli, Italy
    Cancer Biol Ther 3:470-6. 2004
    ..These results suggest that Rb-1 can be a useful molecular target for the therapy of this subset of patients...
  51. ncbi Alpha-interferon and its effects on signalling pathways within cells
    Michele Caraglia
    Dipartimento di Biochimica e Biofisica, Seconda Universita di Napoli, Via Costantinopoli, 16 80138, Naples, Italy
    Curr Protein Pept Sci 5:475-85. 2004
    ..These data strongly suggest that the specific disruption of the latter could be a useful approach to potentiate the antitumour activity of IFNalpha against human tumours based on the new mechanistic insights achieved in the last years...
  52. ncbi Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state
    Chiara Laezza
    IEOS, CNR, Naples, Italy
    J Mol Med (Berl) 86:1341-51. 2008
    ..Lovastatin antitumor efficacy in K-ras-dependent thyroid tumors was further confirmed in vivo, proposing a new therapeutic strategy for those tumor diseases that are sustained by an inappropriate K-ras expression...
  53. ncbi Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents
    Alfredo Budillon
    Experimental Pharmacology Unit, Department of Experimental Oncology, National Cancer Institute Fondazione G Pascale, Naples, Italy
    Recent Pat Anticancer Drug Discov 2:119-34. 2007
    ....
  54. ncbi Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death
    Emilio Chiosi
    Department of Biochemistry and Biophysics, Second University of Naples, Medical School, 80138 Naples, Italy
    J Interferon Cytokine Res 27:589-97. 2007
    ....
  55. ncbi Highlights of the Pananemia National Meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia. Sorrento, Italy, 19-20 December 2008
    Raffaele Addeo
    UOC Oncologia, S Giovanni di Dio Hospital, ASL Napoli 3 Frattaminore, Naples, Italy
    Expert Opin Pharmacother 10:1089-93. 2009
    ..This Italian meeting, sponsored by the Italian Southern Oncological Group (GOIM) and Southern Pananemia Study Group, focused on various aspects of cancer-related anemia and its treatment options...
  56. ncbi Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI)
    Claudia Pizzi
    Dipartimento di Endocrinologia e Oncologia Sperimentale e Clinica, , Naples, Italy
    Anticancer Res 22:727-32. 2002
    ....
  57. ncbi Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report
    Raffaele Addeo
    UOC Oncologia, S Giovanni di Dio Hospital, ASL Napoli3 Via Giovanni XXIII 80020 Frattaminore, Naples, Italy
    Support Care Cancer 16:209-14. 2008
    ..We studied the safety and the effect of a new bisphosphonate, zoledronic acid (ZA), on pain and on quality of life (QoL) in elderly patients with bone metastases...
  58. ncbi W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac
    Ivana Sirangelo
    Dipartimento di Biochimica e Biofisica, Seconda Universita degli Studi di Napoli, Napoli, Italy
    J Cell Physiol 221:412-23. 2009
    ..Our results indicate a role for Ras and Rac in the induction of both intracellular ROS increased levels and apoptosis mediated by PFAs and disclose a new scenario of intervention in neurodegenerative diseases...
  59. ncbi Gamma-glutamyl 16-diaminopropane derivative of vasoactive intestinal peptide: a potent anti-oxidative agent for human epidermoid cancer cells
    Paola Stiuso
    Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli 16, 80138, Naples, Italy
    Amino Acids 39:661-70. 2010
    ..These data suggest that VIP-DAP3 has a stronger anti-oxidative activity as compared to VIP likely based on its super-agonistic binding on the putative receptor...
  60. ncbi Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series
    Liliana Montella
    Medical Oncology Unit, San Giovanni di Dio Hospital, via Domenico Pirozzi, Frattamaggiore, Naples, Italy
    Cancer Chemother Pharmacol 65:1137-43. 2010
    ..In particular, we evaluated the role of zoledronic acid in these patients especially with regard to pain reduction, analgesic drug consumption and safety...
  61. ncbi Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients
    Raffaele Addeo
    Oncology Department, S. Giovanni di Dio Hospital, ASL Napoli 3, 80028 Frattaminore, Naples, Italy
    Oncol Rep 12:135-40. 2004
    ..These results demonstrate the feasibility of this schedule which offers a suitable alternative regimen to treat elderly patients with NHL and shows a good efficacy and an acceptable toxicity profile...
  62. ncbi Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation
    Michele Caraglia
    Experimental Oncology Department, National Cancer Institute Fondazione G Pascale, Naples, Italy
    Cancer Biol Ther 4:1159-67. 2005
    ..These effects likely occurred through the disruption of critical survival pathways and the inactivation of multi-chaperone complex...
  63. ncbi Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
    Bruno Vincenzi
    Department of Surgical and Oncological Sciences, Section of Medical Oncology Università di Palermo, Palermo, Italy, Via del Vespro 127, 90127 Palermo, Italy
    Oncologist 15:85-92. 2010
    ..This study was conducted to assess the link between the antitumor efficacy of sorafenib and its early cutaneous side effects in advanced HCC patients...
  64. ncbi Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer
    Raffaele Addeo
    Dipartimento di Oncologia, S Giovanni di Dio Hospital, Frattaminore, Naples, Italy
    Clin Breast Cancer 10:301-6. 2010
    ..This study sought to determine the safety and activity of oral vinorelbine (VNB), using a metronomic schedule of administration, in elderly patients with metastatic breast cancer (MBC)...
  65. ncbi Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL)
    Raffaele Addeo
    Pediatric Oncology Service, Pediatric Department, II University of Naples, Naples, Italy
    Cancer Biol Ther 4:32-8. 2005
    ..Moreover, p53 alterations were uncommon and alone not strong independent predictors of outcome, but they were correlated to poor response to therapy with PDN and inversely correlated to EFS and OS in univariate analysis...
  66. ncbi Molecular dynamics simulation and automated docking of the pro-apoptotic Bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70
    Fabrizio Mancinelli
    Department of Biochemistry and Biophysics, , 80138 Napoli, Italy
    J Cell Biochem 99:305-18. 2006
    ....
  67. ncbi Cetuximab is an active treatment of metastatic and chemorefractory thymoma
    Giovannella Palmieri
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Front Biosci 12:757-61. 2007
    ..Therefore, both patients are still on therapy. This preliminary experience suggests that cetuximab may be a useful therapeutic choice in advanced pre-treated thymic tumors...
  68. ncbi Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age
    Raffaele Addeo
    Oncology Unit, U O C Oncology, S Giovanni di Dio Hospital, ASL Napoli 3, Via Giovanni XXIII, 80028, Frattaminore, Naples, Italy
    Cancer Chemother Pharmacol 62:285-92. 2008
    ....
  69. ncbi Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy
    Raffaele Addeo
    Second University of Naples, Department of Biochemistry and Biophysics, Via Costantinopoli, 16 80138, Naples, Italy
    Expert Opin Investig Drugs 18:373-8. 2009
    ..Finally, the final results of the So.Lar. study on the Sorafenib + octreotide long-acting release (LAR) combination were presented...
  70. ncbi Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells
    Michele Caraglia
    Department of Biochemistry and Biophysics, Second University of Naples, Italy
    J Cell Physiol 204:539-48. 2005
    ....
  71. ncbi Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors
    Francesco Caponigro
    Division of Medical Oncology B, National Tumor Institute of Naples, Fondazione G Pascale, Naples, Italy
    Curr Opin Oncol 17:212-7. 2005
    ..To discuss future therapeutic strategies...
  72. ncbi Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases
    Raffaele Addeo
    Oncology Unit, S Giovanni di Dio Hospital, Naples, Italy
    Cancer 113:2524-31. 2008
    ..Temozolomide (TMZ), an oral methylating imidazotetrazinone, has antitumor activity against gliomas, malignant melanomas, and brain metastasis and is presently administered as a 5-day oral schedule every 4 weeks...
  73. ncbi Effects of VIP and VIP-DAP on proliferation and lipid peroxidation metabolism in human KB cells
    Michele Caraglia
    Dipartimento di Biochimica e Biofisica, , Via Costantinopoli 16, 80138 Napoli, Italy
    Ann N Y Acad Sci 1070:167-72. 2006
    ..However, we have studied their role in cell cycle modulation and antioxidant activity in the oropharyngeal epidermoid carcinoma KB cells...
  74. ncbi Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours
    Daniele Santini
    Clinical Oncology, University Campus Bio Medico, 00155 Rome, Italy
    Oncol Rep 15:1351-7. 2006
    ..Future clinical trials should be designed to prospectively evaluate the prognostic role of reduction of betaCTX and VEGF in response to ZOL to predict clinical and skeletal outcome...
  75. ncbi Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    Nat Clin Pract Oncol 3:325-38. 2006
    ..We briefly discuss identification of new molecular targets of bisphosphonates from genomic and proteomic analysis, and highlight the cellular consequences of drug-related enzyme inhibition...
  76. ncbi Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
    Daniele Santini
    Medical Oncolog, University Campus Bio Medico, Rome, Italy
    Clin Cancer Res 13:4482-6. 2007
    ....
  77. ncbi Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
    Daniele Santini
    Medical Oncology, University Campus Bio Medico, Rome
    Recent Pat Anticancer Drug Discov 1:383-96. 2006
    ..The translation into the clinical setting of the preclinical evidence of an antiangiogenic power of these drugs is becoming an imperative need and should represent the objective of future clinical trials...
  78. ncbi EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy
    Michele Caraglia
    Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumors Fondaz G Pascale of Naples, Italy
    Recent Pat Anticancer Drug Discov 1:209-22. 2006
    ....
  79. ncbi Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells
    Carla Esposito
    Dipartimento di Chimica, , Via S. Allende 1-84081 Baronissi, Salerno, Italy
    Biochem J 370:205-12. 2003
    ..In conclusion, we demonstrate for the first time that tTG is ubiquitinated and degraded by a proteasome-dependent pathway. Moreover, IFNalpha can, at least in part, induce apoptosis through the modulation of this pathway...
  80. ncbi Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells
    Elena Di Gennaro
    Dipartimento di Oncologia Sperimentale, Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy
    J Cell Physiol 195:139-50. 2003
    ..Overall, these results as well as the timing of the effect of ZD1839 on G1 arrest and p27(KIP1) and p21(CIP1/WAF1) upregulation, suggest a mechanistic connection between these events...
  81. ncbi New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer
    Pierosandro Tagliaferri
    Dipartimento di Medicina Sperimentale e Clinica, Universita Magna Graecia di Catanzaro, Via T Campanella 115, 88100 Catanzaro, Italy
    Cancer Immunol Immunother 54:1-10. 2005
    ..We will review these achievements, and we will specifically address the topic of IFN-alpha-based molecularly targeted combinatory antitumour approaches...
  82. ncbi Highlights of the annual meeting of the Italian Association for Cell Cultures (AICC): new drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6 - 7 December 2007, Naples, Italy
    Michele Caraglia
    National Institute of Tumors Fondazione G Pascale, Experimental Pharmacology Unit, Via Mariano Semmola, 80131 Naples, Italy
    Expert Opin Biol Ther 8:845-54. 2008
    ....
  83. ncbi Highlights of the Annual Meeting of the Italian Association for Cell Cultures (AICC): new drug delivery strategies and technological platforms for diagnosis and therapy of tumors. Part II. 6 - 7 December 2007, Naples, Italy
    Michele Caraglia
    National Institute of Tumors Fondazione G Pascale, Experimental Pharmacology Unit, Via Mariano Semmola, 80131 Naples, Italy
    Expert Opin Biol Ther 8:1031-5. 2008
    ..The crossing of the blood-brain barrier by pegylated liposomes in order to deliver antitumor drugs to brain tumor sites was also explored...
  84. ncbi Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine
    Massimo Donadelli
    Department of Morphological and Biomedical Sciences, Section of Biochemistry, University of Verona, Verona, Italy
    Biochim Biophys Acta 1773:1095-106. 2007
    ....
  85. ncbi Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells
    Antonio Avallone
    National Tumour Institute, Federico II University Medical School, Via M Semmola, 80131 Naples, Italy
    Anticancer Drugs 18:781-91. 2007
    ....
  86. ncbi Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin
    Liliana Montella
    Operative Unit of Medical Oncology, S Giovanni di Dio Hospital, Frattamaggiore, Italy
    Exp Mol Med 36:268-73. 2004
    ..Given the possibility of late disease relapses, the need for long-term follow-up, and reduced delay in treatment of persistent disease, there is still need for greater sensitive diagnostic tools for DTC...
  87. ncbi Emerging anti-cancer molecular mechanisms of aminobisphosphonates
    Michele Caraglia
    Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours, Fondazione G Pascale, Via Mariano Semmola, 80131 Naples, Italy
    Endocr Relat Cancer 13:7-26. 2006
    ..To date, however, the real molecular targets of NBPs are not completely known and new technological platforms are required in order to detect them and to develop new anti-cancer strategies based on the use of NBPs...
  88. ncbi Mitogen-activated protein kinases and asthma
    Girolamo Pelaia
    Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Italy
    J Cell Physiol 202:642-53. 2005
    ..Therefore, this review focuses on the crucial involvement of MAPKs in asthma pathogenesis, thus also discussing their emerging role as molecular targets for anti-asthma drugs...
  89. ncbi Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo
    Francesca Bruzzese
    Experimental Pharmacology Unit, Department of Experimental Oncology, National Cancer Institute G. Pascale, Via M. Semmola, 80131 Naples, Italy
    Clin Cancer Res 12:617-25. 2006
    ..These results provide a rationale for the clinical evaluation of gefitinib in combination with IFN-alpha in HNSCC...